AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00838331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh blood
Description: For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
Study NCT00838331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aged blood
Description: In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (> 28 days; washed or rejuvenated) RBC transfusions.
Study NCT01379274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and azacitidine combination
Description: lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy.
Study NCT02638792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based exposure therapy (I-ET)
Description: The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images.
Study NCT02638792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based stress management therapy
Description: The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
Study NCT02742038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoride varnish plus education
Description: Biannual varnish every 6 month/ 24 months plus educational component
Study NCT02742038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride varnish plus education
Description: Biannual varnish every 6 month/ 24 months plus educational component
Study NCT05011929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: refer to the arm description
Study NCT05011929 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: refer to the arm description
Study NCT03987503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa (SOF/VEL)
Description: a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
Study NCT03987503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of HCV care provided by medical care provider
Study NCT03987503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan® 430 Mini Plus
Description: Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider.
Study NCT01309659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose
Description: Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
Study NCT01309659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron sucrose
Description: Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
Study NCT03757533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: 10 phone calls with a trained health coach
Study NCT03757533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveys
Description: Surveys to assess Behavioural and Psychosocial measures
Study NCT03757533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Surveys to assess Behavioural and Psychosocial measures
Study NCT01996800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulative Therapy (SMT)
Description: Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
Study NCT01996800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy (SMT)
Description: Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
Study NCT01996800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMT and Neuromuscular Reeducation
Description: Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
Study NCT04010396 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling: 1 EDTA and 1 Serum vial
Study NCT00977951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradermal avotermin
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
Study NCT00977951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradermal avotermin
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
Study NCT00977951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
Study NCT00977951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
Study NCT01967199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting balloon expandable stent
Description: Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
Study NCT02989415 — intervention group
Intervention type: OTHER
Intervention: Mechanical Ventilation
Description: Mechanical ventilation during robotic surgery
Study NCT01857661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sound generator
Description: hearing aid with an integrated sound generator
Study NCT01857661 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hearing aids with only amplification
Study NCT02024542 — intervention group
Intervention type: OTHER
Intervention: Surgery
Description: Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing \& counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
Study NCT04517747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: chemotherapy i.v.
Study NCT01967199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel eluting balloon
Description: paclitaxel eluting balloon (SeQuent Please)
Study NCT04517747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: p.o. twice daily
Study NCT03571646 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Capnostream 20 monitoring
Description: Continuous monitoring on a general ward
Study NCT03571646 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PM1000N-RR monitoring
Description: Continuous monitoring on a general ward
Study NCT00189930 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-nef
Description: 3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm
Study NCT00189930 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IMVAMUNE
Description: 3 immunizations: 1E8_TCID50 IMVAMUNE
Study NCT04069858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching to Generic Entecavir (Baracle®)
Description: switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
Study NCT02764736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
Study NCT00522353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligofructose
Description: 21 grams per day in distributed over 3 doses per day for 3 months
Study NCT00522353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
Study NCT00801879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin calcium ointment, 2%
Description: 0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
Study NCT00801879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
Study NCT00612235 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine
Description: Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
Study NCT00612235 — intervention group
Intervention type: DRUG
Intervention: Levetiracetam
Description: Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
Study NCT00612235 — intervention group
Intervention type: DRUG
Intervention: Carbamazepine
Description: Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
Study NCT00612235 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was given
Study NCT04948918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anatomically optimized distal renal denervation
Description: Bilateral radiofrequency renal denervation will be performed using Symplicity Spyral renal denervation system. Generally, at least two separate applications of radiofrequency energy will be performed in each segmental branch of renal artery. Each application will be done through 4 electrodes deployed in helical manner according to the design of the catheter
Study NCT04925232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation device
Description: Five days a week for 2 consecutive weeks, participants will have repetitive TMS at specific paramaters
Study NCT02590588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib daily until unacceptable toxicity or disease progression.
Study NCT02362958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib and capecitabine or vinorelbine
Description: lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
Study NCT01138241 — intervention group
Intervention type: OTHER
Intervention: Tc99mDTPA renal clearance
Description: Tc99mDTPA renal clearance only for 200 patients~1. Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~2. serum creatinine prior and during TDF~3. TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~4. stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~5. serum for cystanin C ( stored sample prior taking ARV and present time)~6. intensive 24 hours pharmacokinetic study of TDF in 20 patients
Study NCT01743755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablet 6 mg, once daily for four consecutive days
Study NCT01743755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, once daily for four consecutive days
Study NCT03098823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAYOS
Description: FDA approved RAYOS for indication of fatigue in Lupus.
Study NCT03098823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: FDA approved corticosteroid frequently used for SLE.
Study NCT01441037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol, 800 mg daily by mouth for 2 years
Study NCT00763815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00763815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00763815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00763815 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT00763815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Dose to be kept stable.
Study NCT00218413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 100 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
Study NCT00763815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Dose to be kept stable.
Study NCT00763815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT00763815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT00218413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 200 μg, Formulation A, on Days 0, 21, 42, 91 \& 182
Study NCT00886301 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: liver biopsy
Description: liver biopsy
Study NCT00678405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathlessness Intervention Service
Description: Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer \& non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).
Study NCT00678405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care (Standard Care)
Description: Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
Study NCT01202656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: One infusion of G-CSF 300 units administered by intrauterine infusion
Study NCT01202656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: One infusion of G-CSF 300 units administered by intrauterine infusion
Study NCT00218413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 200 μg, Formulation B, on Days 0, 21, 42m 91 \& 182
Study NCT00218413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 300 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
Study NCT00218413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NicVAX
Description: 400 μg, Formulation B, on Days 0, 21, 42, 91 \& 182
Study NCT01202656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: intrauterine saline infusion 1 cc
Study NCT01202656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intrauterine saline infusion 1 cc
Study NCT04986462 — intervention group
Intervention type: PROCEDURE
Intervention: shoulder arthroscopy
Description: Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
Study NCT04153721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Name Digital Solution
Description: The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team
Study NCT04427215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Description: Five types of Complementary and alternative medicines (Music Therapy, Art Therapy, Dance-Movement Therapy, Bibliotherapy, Physical Activity) will be applied twice a week.
Study NCT02385318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate (Perrigo)
Study NCT02385318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Reference)
Study NCT02385318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study NCT01780662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT00423605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem®
Description: flexible dosing